Suggested remit - To appraise the clinical and cost effectiveness of mexiletine within its marketing authorisation for treating myotonia in adults with non-dystrophic myotonic disorders.
Status Proposed
Process STA 2018

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 January 2019 (10:00) Scoping workshop (London)
19 November 2018 - 17 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 1488

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance